enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. 3 Things You Need to Know if You Buy CRISPR Therapeutics Today

   www.aol.com/3-things-know-buy-crispr-144500442.html

   Image source: CRISPR Therapeutics. 2. Profitability remains elusive. There's some optimism that CRISPR Therapeutics is still in the early stages of a significant long-term opportunity.

3. CRISPR Stocks: Buy or Trade? - AOL

   www.aol.com/news/crispr-stocks-buy-trade...

   Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks? ... News. Science & Tech. Shopping. Sports. Weather ...

4. CRISPR Science and Stocks: Knowing Enough to Invest - AOL

   www.aol.com/news/crispr-science-stocks-knowing...

   For premium support please call: 800-290-4726 more ways to reach us

5. Intellia Therapeutics - Wikipedia

   en.wikipedia.org/wiki/Intellia_Therapeutics

   Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]

6. The Code Breaker - Wikipedia

   en.wikipedia.org/wiki/The_Code_Breaker

   The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race is a non-fiction book authored by American historian and journalist Walter Isaacson. Published in March 2021 by Simon & Schuster , it is a biography of Jennifer Doudna , the winner of the 2020 Nobel Prize in Chemistry for her work on the CRISPR system of gene ...

7. CRISPR Therapeutics - Wikipedia

   en.wikipedia.org/wiki/CRISPR_Therapeutics

   CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. [6] Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically ...

8. 3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data - AOL

   www.aol.com/news/3-biotech-stocks-intellias...

   Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.

9. Mammoth Biosciences - Wikipedia

   en.wikipedia.org/wiki/Mammoth_Biosciences

   Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells. [5] Also in 2020, both Mammoth Biosciences and Sherlock Biosciences from the Broad Institute used their similar CRISPR technologies to develop tests for ...